Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Co
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....25/PRNewswire/--Formanybusinesses,2009hasbeenapai...fastestgrowingnetworkofexpertphysiciansspecializin...ones has grownthenumberof physiciansinitsnetwork...progresstoaddmorephysician-ownedcenters,includingo...year ,BodyLogicMDhasopened13newbioidenticalhormone...
(Date:11/25/2009)...FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA )an...chiefexecutiveofficer,willpresentatthePiperJaffray...tailsareasfollows:,PiperJaffray21stAnnualHealthCa...p.m.EasternTime,Location:TheNewYorkPalaceHotel,New...t/ireye/,target=,_blank,title=,http://www.corpora...
(Date:11/24/2009)...ork investment bank KTA Capital,s client Neuren Ph...il convertible note private placement with a U.S. ...arranged by KTA Capital as Neuren,s exclusive plac... New York (PRWEB) November 23, 2009 -- The indepe...quot;KTA Capital") has announced that its cli...
(Date:11/24/2009)...FirstCall/--Sigma-AldrichCorporation(Nasdaq: SIAL ...,December1stat1:45PMGMTinLondon,7:45AMUS/CST.Inter...nternetavailableat http://inve s tor.sig m a ...ccessthisfile. ,, AboutSigma-Aldrich: Sigma-...ny.Itschemicalandbiochemicalproductsandkitsareused...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...able in German . , The enzyme DFPase from the ...fficiently detoxify chemical warfare agents such a...ks in 1995. A detailed understanding ,of the mecha...is ,necessary for efforts aiming to improve their ...ity of Frankfurt, the Bundeswehr Institute ,for Ph...
...ril 17 Keystone Symposia on Molecular and Cellula...ogy of RNA Silencing" on April 25, 2009 at the Fai...ia. This will be an opportunity to hear two Nobel ...Fire of Stanford University will deliver a keyno...es in the Small RNA-ome." On Monday morning, April...
... Angela Shen-Hsieh, Founder of Visual I|O has be...dest and largest membership organization for desig...s intelligence software, that lets users throughou...ally with structured and unstructured data for rev...analysis. , New York, NY ...
Other Biology Technology:Structure of enzyme against chemical warfare agents determined 2Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference 2Angela Shen-Hsieh of Visual I|O Named to Board of Directors of AIGA: Oldest and Largest Membership Organization for Designers 2Angela Shen-Hsieh of Visual I|O Named to Board of Directors of AIGA: Oldest and Largest Membership Organization for Designers 3
(Date:11/25/2009)...y assistant professors recently received funding f...nue research beneficial to understanding the envir...topher Blackwood, assistant professor in the Depar...o support two separate research projects. , His ...r Communities and Functions from the Leaf to the L...
(Date:11/24/2009)...tute (LRI) today named 12 new grant recipients for...e innovative work across a broad spectrum of lupus... novelty, and potential to drive scientific discov...plex disease of systemic lupus. , The 2009 grant... across the nation and include interdisciplinary a...
(Date:11/24/2009)...d and flabby arteries from collapsing have been tr... are no longer needed -- once the arteries are str...ctors had no choice but to leave them in place. ,...Department of Biomedical Engineering has developed...drugs where they,re needed, then dissolves. , "O...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Utah ethicist heads stem cell panel 10048 1Utah ethicist heads stem cell panel 10048 2Utah ethicist heads stem cell panel 10048 3Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 1Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 2Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 3Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 4Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 1Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 2Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 3Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 4Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 5Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 6Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 7Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 8
...of a therapeutic cancer vaccine combining the synt... Coley Pharmaceutical), with a peptide antigen wer...igation. The paper shows that the CpG 7909 DNA seq...bility to recognize and destroy cancer cells. The ... of the Ludwig Institute for Cancer Research (LICR...
...ice in field trials in China report higher crop yi...lated health problems, according to a study by res...e University of California, Davis. , Results of t...journal Science. , "This paper studies two of the ...oduction trials, the last step before commercializ...
...tion robbed Elma Phifer of her vision two decades ...eas and reduced the ability of her eyes to soothe ...ame to rely upon family and friends to help her do...sometimes take for granted. Now, twenty years and ... again, thanks to advances in ophthalmology resear...
Other Biology News:Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2Genetically modified rice in China benefits farmers' health, study finds 2Genetically modified rice in China benefits farmers' health, study finds 3Genetically modified rice in China benefits farmers' health, study finds 4Artifical cornea lets woman blind 20 years see 2Artifical cornea lets woman blind 20 years see 3Artifical cornea lets woman blind 20 years see 4
...e DNA quantitation kit is used to quantitate doubl...esence of RNA or protein. With this kit, DNA is st...d with a VersaFluor or other fluorometer. The kit ...5 micrograms per ml and contains Hoechst 33258, ca...
Pokeweed Mitogen Spleen Cell Conditioned Medium, 25 mL from StemCell Technologies, Inc.
PROTEIN G PLUS AGAROSE from Pierce Biotechnology, Inc.
MagNA Pure LC Instrument from Roche Applied Science
Biology Products: